gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · TNXPHealthcarePharmaceuticals

Tonix Pharmaceuticals Holding Corp. (TNXP)

$5.18−0.19%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$5.19▼ 72.33% in range
Nov 3, 2025Low $5.10 · High $19.89Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Tonix Pharmaceuticals Holding closed at $5.18 on Nov 4, down 0.19%, within 1.6% of its 52-week closing low. Volume of 222.6K shares was 0.24× its 20-day average (below normal).

Split-adjusted performance: -32.7% over one month, -64.7% over six months, -72.4% over one year.

In the quarter ended Jun 30, 2026, revenue was $13.54M, up 577.9% from a year earlier, with a net margin of -299.4%.

Short interest was 2.9M shares at the Oct 15 settlement (17.5% of float, 2.4 days to cover).

Market cap$88.8M17.2M shares
Revenue · quarter$13.5M+577.9% YoY
Diluted EPS$-2.44—
P/E · TTM—P/S 3.1×
Net margin-299.4%Gross 94.8%
Dividend yieldNone
52-week range5.10 – 19.89−74.0% from high
Volume222.6K0.24× 20-day avg
Volatility · 60d53.5%Annualised
Short % of float17.5%2.4 days to cover
Net cash$176.2MCash $176.2M
Next earnings—Not scheduled
Split-adjusted performance
1W −3.5%1M −32.7%3M −55.5%6M −64.7%YTD −66.8%1Y −72.4%3Y −99.7%5Y −100.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum16
Revenue growth95
Net margin33
Value (low P/E)—
Size39

Industry medians: 6-month return −25.3%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short2.9M+0.1% vs prior
Days to cover2.4Settled Oct 15
% of float17.5%
Short vol. 10d56.1%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
TNXPTonix Pharmaceuticals Holding$5.18−0.19%−64.7%+577.9%−299.4%—$88.8M
NTHINeOnc Technologies Holdings$3.10+0.98%−41.6%———$89.3MCompare
PLYXPolaryx Therapeutics$1.80+4.05%−52.6%———$89.7MCompare
GNLXGenelux$1.94+1.04%−32.4%———$87.8MCompare
PDSBPDS Biotechnology$1.28−9.22%+20.8%———$92.8MCompare
RLYBRallybio$15.71−0.98%+7.9%−100.0%—3.2$84.6MCompare
MISTMilestone Pharmaceuticals$0.7687+1.24%−61.0%—−5118.8%—$95.7MCompare
VTVTvTv Therapeutics$24.30+3.18%−23.3%———$96.1MCompare
FTLFFitLife Brands$8.18+3.68%−12.1%+64.6%7.3%12.3$76.8MCompare

News about Tonix Pharmaceuticals Holding

All news →
Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. LivesGlobeNewswire Inc. · Jun 8, 2026▲ PositiveTonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026GlobeNewswire Inc. · May 14, 2026▲ PositiveTonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug DevelopmentGlobeNewswire Inc. · Apr 15, 2026▲ PositiveTonix Pharmaceuticals to Present at BIO-Europe Spring 2026GlobeNewswire Inc. · Mar 18, 2026▲ Positive

Quick answers

What does Tonix Pharmaceuticals Holding do?
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra.
What is TNXP's market cap?
$88.84M, based on the Nov 4 close of $5.18.
Does Tonix Pharmaceuticals Holding pay a dividend?
No regular cash dividend has been paid in the last year.
How much of TNXP is sold short?
2.9M shares, 17.5% of float, as of Oct 15, 2026.
What sector is TNXP in?
Healthcare, in the Pharmaceuticals industry.

About Tonix Pharmaceuticals Holding

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

HQ: Berkeley Heights, NJ142 employeesListed Feb 13, 2009tonixpharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology